AOD-9604
Also known as: Advanced Obesity Drug 9604, HGH Fragment 177-191
The fat-burning fragment of HGH — targeted lipolysis without blood sugar effects.
Molecular structure image coming soon
Research use only in the US. Has GRAS status as a food ingredient. Consult a healthcare provider.
Overview
AOD-9604 is a modified fragment of human growth hormone (hGH) spanning amino acids 177–191. It was originally developed by Metabolic Pharmaceuticals as an anti-obesity drug. Unlike full HGH, AOD-9604 stimulates fat breakdown (lipolysis) without affecting IGF-1 levels, blood glucose, or muscle growth. It completed Phase III clinical trials for obesity before the drug program was discontinued.
Mechanism of Action
AOD-9604 mimics the lipolytic action of the C-terminal fragment of HGH by activating beta-3 adrenergic receptors in fat tissue, stimulating breakdown of triglycerides. It inhibits lipogenesis (fat storage) without the glucose-elevating effects of full HGH.
Use Cases
- ✓Targeted fat loss (particularly visceral and subcutaneous)
- ✓Body recomposition
- ✓Obesity management
- ✓Metabolism support
Research Summary
AOD-9604 successfully completed Phase I, II, and III clinical trials with an excellent safety profile. Phase IIb trials showed meaningful reductions in body fat vs placebo. The FDA classified it as GRAS (Generally Recognized as Safe) as a food ingredient. Clinical program was discontinued due to modest efficacy relative to emerging GLP-1 options, not safety concerns.
Typical Dosing
250–500 mcg/day, subcutaneous injection, on empty stomach in the morning.
Administration
Research Chemical
Research use only in the US. Has GRAS status as a food ingredient. Consult a healthcare provider.
